Clinical Trials Browser

Phase 1/2 × entinostat × Dermatologic × Clear all

NCT02437136 2025-03-20

Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in Non-small Cell Lung Cancer (NSCLC) With Expansion Cohorts in NSCLC, Melanoma, and Colorectal Cancer (CRC)

Phase 1/2 Completed

191 enrolled 26 charts

DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma